Search
Quercus rubra pollen
go.drugbank.com/drugs/DB10481ApprovedQuercus rubra pollen is the pollen of the Quercus rubra plant. Quercus rubra pollen is mainly used in allergenic testing.
Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenCategories: Non-Standardized Pollen Allergenic ExtractDiacerein
go.drugbank.com/drugs/DB11994ApprovedInvestigationalWithdrawnDiacerein is a prodrug which is metabolized to rhein. … It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780].
Mixtures: CARTIGEN NFCategories: Antiinflammatory and Antirheumatic Products, Non-SteroidsCarglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010. … Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase.
Synonyms: N-Carbamylglutamate, N-Carbamyl-L-glutamateColestipol
go.drugbank.com/drugs/DB00375Approvedbe good candidates for using the agent owing to its physical effects on the gut. … results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaEcabet
go.drugbank.com/drugs/DB05265InvestigationalEcabet is a prescription eye drop for the treatment of dry eye syndrome. … Ecabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia.
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [A246015] Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
Patisiran
go.drugbank.com/drugs/DB14582ApprovedPatisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220]. … It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced.
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme
Lauric acid
go.drugbank.com/drugs/DB03017ApprovedLauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses. … Lauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression.
Synonyms: n-dodecanoic acidFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … [L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770]